We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From May 2019 to May 2024
By Dave Sebastian
The Food and Drug Administration on Monday said it has approved two applications for the first generic version of the blood thinner Eliquis by Mylan NV's (MYL) Mylan Pharmaceuticals Inc. and Micro Labs Ltd.
The tablets, whose generic name is apixaban, prevent stroke in patients with nonvalvular atrial fibrillation and treats deep vein thrombosis and pulmonary embolism, the agency said.
Bristol-Myers Squibb Co. (BMY) makes Eliquis, whose sales rose 22% in the third quarter from the same period last year.
"These approvals mark the first generic approvals of a direct oral anticoagulant," Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in prepared remarks.
Bristol-Myers shares were down 0.2% at $63.39, while Mylan's stock was up 0.6% at $19.92 in afternoon trade.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
December 23, 2019 15:47 ET (20:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
